Although many advances have been made in the early treatment of breast cancer, triple-negative breast cancer (TNBC), which lacks the expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (Her2) [3, 4], is still an obstacle for researchers. Here, ERBB2 is linked to breast carcinoma.